ENTO
Geode Capital Management’s Entero Therapeutics ENTO Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $14.6K | Hold |
36,560
| – | – | ﹤0.01% | 4398 |
|
|
2025
Q1 | $17.6K | Buy |
36,560
+16,703
| +84% | +$8.02K | ﹤0.01% | 4376 |
|
|
2024
Q4 | $12.4K | Buy |
19,857
+3,802
| +24% | +$2.37K | ﹤0.01% | 4427 |
|
|
2024
Q3 | $5.53K | Sell |
16,055
-91
| -0.6% | -$31 | ﹤0.01% | 4513 |
|
|
2024
Q2 | $20.3K | Buy |
16,146
+5,299
| +49% | +$6.68K | ﹤0.01% | 4445 |
|
|
2024
Q1 | $48.3K | Buy |
+10,847
| New | +$48.3K | ﹤0.01% | 4330 |
|
|
2023
Q4 | – | Sell |
-42,340
| Closed | -$12.3K | – | 4693 |
|
|
2023
Q3 | $12.3K | Buy |
+42,340
| New | +$12.3K | ﹤0.01% | 4705 |
|
|
2023
Q1 | – | Sell |
-10,704
| Closed | -$9K | – | 4832 |
|
|
2022
Q4 | $9K | Buy |
+10,704
| New | +$9K | ﹤0.01% | 4850 |
|
|
2022
Q3 | – | Sell |
-91,026
| Closed | -$18K | – | 5045 |
|
|
2022
Q2 | $18K | Hold |
91,026
| – | – | ﹤0.01% | 4940 |
|
|
2022
Q1 | $96K | Buy |
91,026
+10,139
| +13% | +$10.7K | ﹤0.01% | 4675 |
|
|
2021
Q4 | $116K | Buy |
80,887
+33,143
| +69% | +$47.5K | ﹤0.01% | 4678 |
|
|
2021
Q3 | $134K | Sell |
47,744
-385,806
| -89% | -$1.08M | ﹤0.01% | 4587 |
|
|
2021
Q2 | $355K | Buy |
433,550
+176,915
| +69% | +$145K | ﹤0.01% | 4092 |
|
|
2021
Q1 | $343K | Buy |
256,635
+213,550
| +496% | +$285K | ﹤0.01% | 3940 |
|
|
2020
Q4 | $41K | Hold |
43,085
| – | – | ﹤0.01% | 4199 |
|
|
2020
Q3 | $30K | Hold |
43,085
| – | – | ﹤0.01% | 4090 |
|
|
2020
Q2 | $39K | Hold |
43,085
| – | – | ﹤0.01% | 4012 |
|
|
2020
Q1 | $24K | Buy |
+43,085
| New | +$24K | ﹤0.01% | 4023 |
|